

Andrew J Spillane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9604132/publications.pdf>

Version: 2024-02-01

19
papers

1,803
citations

516681

16
h-index

794568

19
g-index

19
all docs

19
docs citations

19
times ranked

1841
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	10.7	346
2	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
3	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	30.7	190
4	Survivorship care plans in cancer: a systematic review of care plan outcomes. <i>British Journal of Cancer</i> , 2014, 111, 1899-1908.	6.4	183
5	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
6	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	1.2	135
7	Neoadjuvant dabrafenib combined with trametinib for resectable, stage III B ⁺ C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	10.7	126
8	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	30.7	121
9	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	1.2	77
10	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	16.8	64
11	Patterns and outcomes of breast reconstruction in older women – A systematic review of the literature. <i>European Journal of Surgical Oncology</i> , 2016, 42, 604-615.	1.0	52
12	High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. <i>Annals of Oncology</i> , 2009, 20, 977-984.	1.2	28
13	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	1.2	22
14	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	1.5	21
15	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335.	4.3	20
16	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. <i>European Journal of Surgical Oncology</i> , 2015, 41, 830-836.	1.0	19
17	Measuring the quality of melanoma surgery – Highlighting issues with standardization and quality assurance of care in surgical oncology. <i>European Journal of Surgical Oncology</i> , 2017, 43, 561-571.	1.0	17
18	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	2.8	1